Bioanalytical Testing Services Market Summary

The global bioanalytical testing services market size was estimated at USD 4.80 billion in 2024 and is projected to reach USD 11.24 billion by 2033, growing at a CAGR of 9.93% from 2025 to 2033. The market growth is due to increasing drug development activities and drug approval processes, increasing complexity of therapeutics, and the rise in outsourcing of testing services. Pharmaceutical and biotechnology companies are relying more on specialized testing partners to accelerate development timelines, ensure regulatory compliance, and manage costs effectively throughout clinical phases.

The development of complex therapeutic modalities, such as gene therapies and biologics, has created a need for specialized bioanalytical testing services. Furthermore, growing technological advancements and increasing R&D investments are also some of the key factors driving market growth. The continuous development of cutting-edge technologies, such as High-Throughput Screening (HTS), liquid chromatography-mass spectrometry (LC-MS), and Next-generation Sequencing (NGS), has significantly enhanced the precision, speed, and sensitivity of bioanalytical testing. These innovations assist service providers in conducting more complex studies and gaining accurate data on drug efficacy, safety, pharmacokinetics, and pharmacodynamics. Moreover, the integration of automation and Artificial Intelligence (AI) into bioanalytical workflows has streamlined processes, reduced human error, and improved throughput, enabling faster and more efficient data generation.

Key Market Trends & Insights

  • North America dominated the bioanalytical testing services market with the largest revenue share of 47.40% in 2024, supported by strong pharmaceutical R&D activities, favorable regulatory frameworks, and the presence of leading service providers.
  • The bioanalytical testing services industry in the U.S. accounted for the largest market revenue share in 2024 due to continuous innovation, increasing clinical trial volumes, and significant investment in biologics and advanced therapeutics.
  • By molecule, the small molecule segment led the market with the largest revenue share of 55.67% in 2024, as small-molecule drugs remain widely developed and require extensive bioanalytical evaluation throughout their lifecycle.
  • By test, the bioequivalence segment accounted for the largest market revenue share in 2024, driven by a surge in generic drug development and the need to demonstrate clinical similarity to branded drugs for regulatory approval.

Order a free sample PDF of the Bioanalytical Testing Services Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

  • 2024 Market Size: USD 4.80 Billion
  • 2033 Projected Market Size: USD 11.24 Billion
  • CAGR (2025-2033): 9.93%
  • North America: Largest market in 2024
  • Asia-Pacific: Fastest growing market

Key Companies & Market Share Insights

Key players in the bioanalytical testing services industry are actively expanding their service portfolios, investing in advanced analytical technologies, and pursuing strategic partnerships to strengthen their global presence. Leading contract research organizations (CROs) and specialized laboratories are enhancing capabilities in complex assay development, large molecule analysis, and cell and gene therapy testing to meet evolving client needs. For instance, in August 2024, SGS introduced its new specialized bioanalytical testing services in Hudson, New Hampshire, North America. Through these services, the company provides advanced bioanalytical services to both biopharmaceutical and pharmaceutical companies.

Key Players

  • Thermo Fisher Scientific Inc (PPD, Inc.)
  • ICON Plc
  • Charles River Laboratories International
  • IQVIA
  • Syneos Health
  • SGS SA
  • Labcorp
  • Intertek Group Plc
  • Pace Analytical Services LLC.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The global bioanalytical testing services market is positioned for strong and sustained growth as pharmaceutical innovation accelerates and regulatory requirements become increasingly stringent. The shift toward outsourcing complex analytical activities enables companies to access advanced technologies, specialized expertise, and scalable testing capabilities. With rising demand for biologics, gene therapies, and personalized medicines, the need for comprehensive and accurate analysis continues to expand. Automated platforms, AI-driven data solutions, and advancements in mass spectrometry and genomic testing will further enhance service efficiency. As clinical trials grow globally, reliance on trusted bioanalytical partners will remain crucial, ensuring continued market expansion over the coming years.